AU2010274921B2 - 1H-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis - Google Patents

1H-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis Download PDF

Info

Publication number
AU2010274921B2
AU2010274921B2 AU2010274921A AU2010274921A AU2010274921B2 AU 2010274921 B2 AU2010274921 B2 AU 2010274921B2 AU 2010274921 A AU2010274921 A AU 2010274921A AU 2010274921 A AU2010274921 A AU 2010274921A AU 2010274921 B2 AU2010274921 B2 AU 2010274921B2
Authority
AU
Australia
Prior art keywords
dihydro
dioxo
quinazolin
methanesulfonamide
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2010274921A
Other languages
English (en)
Other versions
AU2010274921A1 (en
Inventor
Hans O. Kalkman
Henri Mattes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010274921A1 publication Critical patent/AU2010274921A1/en
Application granted granted Critical
Publication of AU2010274921B2 publication Critical patent/AU2010274921B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010274921A 2009-07-23 2010-07-23 1H-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis Expired - Fee Related AU2010274921B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22794009P 2009-07-23 2009-07-23
US61/227,940 2009-07-23
PCT/EP2010/060733 WO2011009951A1 (en) 2009-07-23 2010-07-23 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis

Publications (2)

Publication Number Publication Date
AU2010274921A1 AU2010274921A1 (en) 2012-02-02
AU2010274921B2 true AU2010274921B2 (en) 2014-08-14

Family

ID=42671655

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010274921A Expired - Fee Related AU2010274921B2 (en) 2009-07-23 2010-07-23 1H-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis

Country Status (12)

Country Link
US (1) US20120122903A1 (enExample)
EP (1) EP2456442A1 (enExample)
JP (1) JP2012533605A (enExample)
KR (1) KR20120052341A (enExample)
CN (1) CN102470137A (enExample)
AU (1) AU2010274921B2 (enExample)
BR (1) BR112012001258A2 (enExample)
CA (1) CA2768333A1 (enExample)
IN (1) IN2012DN00235A (enExample)
MX (1) MX2012000956A (enExample)
RU (1) RU2012106426A (enExample)
WO (1) WO2011009951A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5976011B2 (ja) * 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108591A1 (en) * 2005-04-11 2006-10-19 Novartis Ag 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108591A1 (en) * 2005-04-11 2006-10-19 Novartis Ag 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELGER et al, ChemMedChem, 2006, 1, 1142-1148 *
KOVACS et al, Experimental Neurology, 2008, 209, 288-291 *

Also Published As

Publication number Publication date
CN102470137A (zh) 2012-05-23
KR20120052341A (ko) 2012-05-23
AU2010274921A1 (en) 2012-02-02
BR112012001258A2 (pt) 2016-02-10
JP2012533605A (ja) 2012-12-27
CA2768333A1 (en) 2011-01-27
EP2456442A1 (en) 2012-05-30
MX2012000956A (es) 2012-02-28
IN2012DN00235A (enExample) 2015-05-01
RU2012106426A (ru) 2013-08-27
US20120122903A1 (en) 2012-05-17
WO2011009951A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
EP3781564B1 (en) Pyridazine derivatives for the treatment of cancer
EP2010505B1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
ES2745824T3 (es) Inhibidores de SSAO derivados de imidazo[4,5-c]piridina
JP5913631B2 (ja) Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ピリドフタラジノン
ES2734552T3 (es) Compuestos novedosos para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide
ES2565229T3 (es) Derivados 2-amino-4-(piridin-2-il)-5,6-dihidro-4H-1,3-oxazina y su uso como inhibidores de BACE-1 y/o BACE-2
AU2014204831C1 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
CA2573103A1 (en) Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
WO2016112847A1 (zh) Egfr激酶抑制剂喹唑啉并杂环化合物、制备及应用
KR20090107068A (ko) 헤테로시클리덴-ｎ-(아릴)아세트아미드 유도체
CA2895162C (en) Methods and compositions for inhibiting cnksr1
JP7319369B2 (ja) ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
EP2985283A1 (en) Anti-angiogenesis compound, intermediate and use thereof
JP2005247864A (ja) ８−アザ、６−アザ、および６，８−ジアザ−１，４−ジヒドロキノキサリン−２，３−ジオン類
US20250144115A1 (en) Amide compound as potassium channel regulator, and preparation therefor and use thereof
TW200914451A (en) New compounds
TW202416989A (zh) 作為pi3k抑制劑的苯并嘧啶-4(3h)-酮
AU2017317111A1 (en) Triazolopyrazinone derivative useful as a human PDE1 inhibitor
AU2010274921B2 (en) 1H-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis
JP2017516829A (ja) ピリドピリミジンジオン誘導体
WO2020210337A1 (en) Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
MX2012010570A (es) Compuestos de benzazepina.
ES2973452T3 (es) Compuesto de tetrahidro-1H-benzazepina como modulador del canal de potasio, método de preparación y uso del mismo
CA3083398C (en) Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease
WO2012063513A1 (en) Method of treatment for mental disorders

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee